Abstract:Obesity is a critical health condition worldwide that increases the risks of comorbid chronic diseases, but it can be managed with weight loss. However, conventional interventions relying on diet and exercise are inadequate for achieving and maintaining weight loss, thus there is significant market interest for pharmaceutical anti-obesity agents. For decades, receptor agonists for the gut peptide glucagon-like peptide 1 (GLP-1) featured prominently in anti-obesity medications by suppressing appetite and food reward to elicit rapid weight loss. As the neurocircuitry underlying food motivation overlaps with that for drugs of abuse, GLP-1 receptor agonism has also been shown to decrease substance use and relapse, thus its therapeutic potential may extend beyond weight management to treat addictions. However, as prolonged use of anti-obesity drugs may increase the risk of mood-related disorders like anxiety and depression, and individuals taking GLP-1-based medication commonly report feeling demotivated, the long-term safety of such drugs is an ongoing concern. Interestingly, current research now focuses on dual agonist approaches that include GLP-1 receptor agonism to enable synergistic effects on weight loss or associated functions. GLP-1 is secreted from the same intestinal cells as the anorectic gut peptide, Peptide YY3-36 (PYY3-36), thus this review assessed the therapeutic potential and underlying neural circuits targeted by PYY3-36 when administered independently or in combination with GLP-1 to curb the appetite for food or drugs of abuse like opiates, alcohol, and nicotine. Additionally, we also reviewed animal and human studies to assess the impact, if any, for GLP-1 and/or PYY3-36 on mood-related behaviors in relation to anxiety and depression. As dual agonists targeting GLP-1 and PYY3-36 may produce synergistic effects, they can be effective at lower doses and offer an alternative approach for therapeutic benefits while mitigating undesirable side effects.

Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects

Ghrelin and the brain-gut axis as a pharmacological target for appetite control.

Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status

Future directions in obesity pharmacotherapy

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives

Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update

Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3-36 in the suppression of food, drug-seeking, and anxiogenesis

Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?

The incretin/glucagon system as a target for pharmacotherapy of obesity

Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

GLP-1 and Amylin in the Treatment of Obesity

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

The role of incretin receptor agonists in the treatment of obesity

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus

A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity

Drug Therapy in Obesity: A Review of Current and Emerging Treatments